Alnylam Pharmaceuticals, Inc.
ALNY
$221.20
$4.221.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 327.74% | 1,228.66% | 322.56% | 325.05% | -327.66% |
| Total Depreciation and Amortization | -0.32% | -5.91% | -4.67% | -1.28% | -7.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.06% | 44.96% | -55.80% | 164.16% | -1.50% |
| Change in Net Operating Assets | -208.10% | -35.92% | 32.45% | -598.92% | 168.19% |
| Cash from Operations | 151.70% | 158.60% | 272.78% | 643.84% | 4.55% |
| Capital Expenditure | -142.64% | -143.40% | -156.12% | -189.65% | -78.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -158.70% | -103.02% | 68.34% | 2,069.64% | -402.89% |
| Cash from Investing | -157.08% | -122.45% | 29.76% | 1,756.55% | -516.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -58.68% | -73.35% | 14.95% | -28.04% | -38.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 175.55% | 177.89% | 1,170.82% | -507.38% | -176.29% |
| Cash from Financing | -53.35% | -65.90% | 46.20% | -536.33% | -40.93% |
| Foreign Exchange rate Adjustments | -108.89% | -150.25% | 66.99% | -106.14% | 981.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.14% | 0.03% | 224.03% | 187.07% | -67.32% |